Overview

Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine what effects (good and bad) bevacizumab and temozolomide have on patients with neuroendocrine tumors.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Genentech, Inc.
Massachusetts General Hospital
Schering-Plough
Treatments:
Bevacizumab
Dacarbazine
Temozolomide